

Acute lymphoblastic leukaemia first-line – dasatinib – initial (induction and consolidation) authority application

Online PBS Authorities



You do not need to complete this form if you use the **Online PBS Authorities** system.

For more information and how to access the **Online PBS Authorities** system, go to servicesaustralia.gov.au/hppbsauthorities

When to use this form

Use this form to apply for **initial** PBS-subsidised dasatinib as first-line induction and consolidation therapy for patients with acute lymphoblastic leukaemia.

Important information

Initial applications to start PBS-subsidised induction and consolidation therapy can be made using the **Online PBS Authorities** system or in writing and must include sufficient information to determine the patient's eligibility according to the PBS criteria.

Under no circumstances will phone approvals be granted for acute lymphoblastic leukaemia first-line **initial (induction and consolidation)** authority applications.

The information in this form is correct at the time of publishing and may be subject to change.

Continuing treatment

This form is **ONLY** for **initial (induction and consolidation)** treatment.

After an authority application for **initial (induction and consolidation)** treatment has been approved, applications for **continuing (maintenance of first complete remission)** treatment can be made in real time using the **Online PBS Authorities** system or by phone. Call 1800 700 270 Monday to Friday, 8 am to 5 pm, local time.

Treatment specifics

Allogeneic stem cell transplantation is the preferred therapy for eligible patients achieving a complete remission of Philadelphia positive acute lymphoblastic leukaemia.

For more information

Go to servicesaustralia.gov.au/healthprofessionals

Acute lymphoblastic leukaemia first-line – dasatinib – initial (induction and consolidation) authority application

Online PBS Authorities



You do not need to complete this form if you use the
Online PBS Authorities system.

Go to servicesaustralia.gov.au/hppbsauthorities

Patient's details

1 Medicare card number

Ref no.

or

Department of Veterans' Affairs card number

2 Family name

First given name

3 Date of birth (DD MM YYYY)

Prescriber's details

4 Prescriber number

5 Family name

First given name

6 Business phone number (including area code)

Alternative phone number (including area code)

Conditions and criteria

To qualify for PBS authority approval, the following conditions
must be met.

7 Does the patient have newly diagnosed acute lymphoblastic leukaemia?

Yes

No

8 Is the patient being treated by a medical practitioner?

Yes

No

9 The patient's condition:

is expressing the Philadelphia chromosome

or

has the transcript BCR-ABL

10 Is the treatment for induction and consolidation therapy?

Yes

No

11 The diagnosis of acute lymphoblastic leukaemia is confirmed by a pathology report conducted on peripheral blood or bone marrow with:

cytogenetic evidence of the Philadelphia chromosome

Date of the pathology report (DD MM YYYY)

or

a qualitative PCR report documenting the presence of the
BCR-ABL transcript.

Date of the pathology report (DD MM YYYY)

12 Is the treatment in combination with chemotherapy or corticosteroids?

Yes

No

13 The patient:

has not previously experienced a failure to respond to the
PBS-subsidised first-line treatment with this drug for this
condition

or

has experienced intolerance, not a failure to respond, to
initial PBS-subsidised treatment with imatinib as a first-line
therapy for this condition



MCA0PB271 2603

Checklist

- 14**  The relevant attachments need to be provided with this form.
- Details of the proposed prescription(s).
 - Pathology cytogenetic report conducted on peripheral blood or bone marrow supporting the diagnosis of acute lymphoblastic leukaemia with cytogenetic evidence of the Philadelphia chromosome
- or
- Pathology cytogenetic report supporting the diagnosis of acute lymphoblastic leukaemia with a qualitative PCR report documenting the presence of the BCR-ABL transcript in either peripheral blood or bone marrow.

Privacy notice

- 15** Personal information is protected by law (including the *Privacy Act 1988*) and is collected by Services Australia for the purposes of assessing and processing this authority application. Personal information may be used by Services Australia, or given to other parties where the individual has agreed to this, or where it is required or authorised by law (including for the purpose of research or conducting investigations). More information about the way in which Services Australia manages personal information, including our privacy policy, can be found at servicesaustralia.gov.au/privacypolicy

Prescriber's declaration

You do not need to **sign** the declaration if you complete this form using Adobe Acrobat Reader and return this form through Health Professional Online Services (HPOS) at servicesaustralia.gov.au/hpos

16 I declare that:

- I am aware that this patient must meet the criteria listed in the current Schedule of Pharmaceutical Benefits to be eligible for this medicine
- I have informed the patient that their personal information (including health information) will be disclosed to Services Australia for the purposes of assessing and processing this authority application
- I have provided details of the proposed prescription(s) and the relevant attachments as specified in the Pharmaceutical Benefits Scheme restriction
- the information I have provided in this form is complete and correct.

I understand that:

- giving false or misleading information is a serious offence.
- I have read, understood and agree to the above.

Date (DD MM YYYY) (you **must** date this declaration)

--	--	--	--	--	--

Prescriber's signature (**only** required if returning by post)



Returning this form

Return this form, details of the proposed prescription(s) and any relevant attachments:

- **online** (no signature required), upload through HPOS at servicesaustralia.gov.au/hpos
- by post (signature required) to
Services Australia
Complex Drugs Programs
Reply Paid 9826
HOBART TAS 7001